Internal Reference Number: FOI_9559
Date Request Received: 17/07/2026 00:00:00
Date Request Replied To: 07/08/2026 00:00:00
This response was sent via: By Email
Request Summary: Treatment of cancers
Request Category: Researcher
| Question Number 1: How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period available? Please see attached | |
| Answer To Question 1: Please see attached To accompany this answer to question 1 please also see the documents listed below:  FOI 9559 - Q1.pdf | |
| Question Number 2: How many patients were treated in total, regardless of diagnosis, with the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? | |
| Answer To Question 2: Please see attached To accompany this answer to question 2 please also see the documents listed below: FOI 9559 Q2.pdf | |
| Question Number 3: How many patients were treated specifically for breast cancer (ICD-10 codes = C50*, D509) in the 3 months between the start of April 2026 and the end of June 2026? | |
| Answer To Question 3: Please see attached To accompany this answer to question 3 please also see the documents listed below: FOI 9559 Q3.pdf | |
| Question Number 4: How many patients received the following medicines with curative treatment intent in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period for which data are available? | |
| Answer To Question 4: Please see attached To accompany this answer to question 4 please also see the documents listed below: FOI 9559 Q4.pdf | |
| Question Number 5: How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period for which data are available? | |
| Answer To Question 5: Please see attached To accompany this answer to question 5 please also see the documents listed below: FOI 9559 Q5.pdf | |
| Question Number 6: How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period for which data are available? | |
| Answer To Question 6: Please see attached To accompany this answer to question 6 please also see the documents listed below: FOI 9559 Q6.pdf | |
| Question Number 7: How many patients were treated with the following medicines in combination in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period available? | |
| Answer To Question 7: Please see attached To accompany this answer to question 7 please also see the documents listed below: FOI 9559 - Q7.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
